Articles tagged with Human Immunodeficiency Virus
A study published in Annals of Internal Medicine found that men with HIV have a greater risk and extent of coronary artery disease compared to uninfected men. Meanwhile, nearly one-third of patients fail to fill their first-time prescriptions, which may impact clinical outcomes.
A study of 882 HIV-infected prisoners found that treating inmates for HIV while incarcerated helped a majority achieve viral suppression by release. Most prisoners achieved viral suppression regardless of age, race, or ART regimen type.
A new study published in AIDS Care found that pressure from counselors and perceived ineffectiveness of interventions can deter young adults from returning for follow-up sessions. The study suggests that tailoring interventions to individual needs, including delivering personalized information about HIV risk, can improve retention rates.
Scientists at the University of Granada have discovered an allosteric interaction between HIV protein gp41 and antibody 2F5, a potent virus neutralizer. This breakthrough could lead to the design of effective vaccines against HIV by understanding how immune responses work.
Patients co-infected with HIV and hepatitis C have an 80 percent higher rate of decompensated cirrhosis than hepatitis C-only patients. Even when ART is effective, they still experience a 60 percent higher risk of serious liver disease compared to those with hepatitis C alone.
A new study calls for increased routine HIV testing among older adults, citing high rates of 'late presentation' and significantly increased mortality. The UK's growing population of older individuals living with HIV requires a more comprehensive approach to care, incorporating mental, functional, and social aspects.
A person with both lupus and HIV was found to produce the correct type of neutralizing antibodies, a key component of an effective vaccine. The study provides new insights into the immune system's response to the virus and could aid in the development of vaccines capable of overcoming tolerance controls.
A Northwestern University-designed intravaginal ring provides both antiretroviral drug and contraceptive protection for months, addressing a significant need in women's reproductive health. The device, known as the tenofovir levonorgestrel IVR, has been engineered to deliver controlled doses of these medications over an extended period.
Research finds that HIV transmissions within communities are often facilitated by sexual contact with partners from outside the community. The study, conducted in Uganda, analyzed data from 46 communities and found that most new infections occur through sex with an outsider.
Researchers analyzed data from the VOICE trial and found that women using injectable contraceptive DMPA were more likely to acquire HIV than those using NET-EN. The study also showed a significant difference in HIV risk between DMPA and NET-EN users, particularly among HSV-2 positive women.
Two new HIV prevention products, a combination antiretroviral vaginal ring and a film releasing the drug dapivirine, show safety and hold promise for further development. The products aim to provide an array of options for women-initiated prevention tools against HIV.
Researchers have discovered potent antibodies in a KwaZulu-Natal woman's blood that can kill multiple strains of HIV. The study, published in Nature, could lead to new HIV vaccine strategies and improve treatment options.
A computer model recommends a combination of interventions, including increased HIV testing, substance abuse treatment, needle and syringe exchange programs, and antiretroviral treatment as prevention to reduce HIV spread in NYC. The result would lower new infections by more than 60% by 2040.
Researchers used Twitter 'big data' to track HIV incidence and drug-related behaviors, mapping where tweets originated and linking them with geographic distribution of HIV cases. The study suggests that monitoring tweets can predict sexual risk and drug use behaviors, potentially preventing outbreaks.
The University of North Carolina has received a seven-year, $40 million award from the NIH for its Global HIV Prevention and Treatment Clinical Trials Unit. The unit will lead research on HIV treatment, prevention, and cure, with a focus on high-risk populations in the US and sub-Saharan Africa.
The UK's mother to child HIV transmission rate has dropped to an all-time low of 0.46%, according to a study published in the journal AIDS. The decline is attributed to earlier initiation of antenatal combination antiretroviral therapy and increased uptake of antenatal HIV screening.
Women living in world regions with high HIV rates are at high risk of acquiring HIV during pregnancy and postpartum. The combined HIV incidence rate among pregnant/postpartum women was 3.8/100 person-years, significantly higher in African countries than non-African countries.
A large-scale survey of South African healthcare workers reveals major gaps in workplace protection against tuberculosis, HIV, and hepatitis. Healthcare workers are at higher risk of contracting these diseases due to lack of screening, vaccination, and proper hygiene practices.
A new Penn Medicine study found that mental health patients are up to four times more likely to be infected with HIV than the general population. Researchers tested over 1,000 patients in care and detected several new HIV cases, highlighting the need for routine testing in mental health settings.
A new analysis of data from the Women's Interagency HIV Study reveals that anxiety is the biggest factor affecting thinking skills in midlife women with HIV. Mental processing speed and verbal memory were more closely linked to depression, anxiety, and hot flashes in both HIV-infected and healthy women.
A group of experts warn that high blood pressure could be as devastating to global health as HIV, with potentially more deaths over the next 20 years. Despite similarities between the two conditions, there is 'denial' and misunderstanding about hypertension's impact, hindering effective treatment and management.
Researchers found a mechanism that helps HIV evade antibodies and stabilize key proteins. By sulfating amino acids on the gp120 protein, the virus can be made more susceptible to neutralizing antibodies, which could lead to more effective HIV vaccines.
Researchers at Caltech used high-resolution electron microscopy to visualize HIV infection in the gut of an infected mouse model. The study revealed novel observations about HIV behavior, including semisynchronous wave patterns of virus release from infected cells and transmission through free pools of virus.
Scientists at UC Berkeley and NIH have captured a high-resolution snapshot of the Nef protein, which hijacks host proteins to facilitate HIV's lethality. By blocking a promising target on host protein AP2, researchers aim to slow or stop HIV.
A new study found differences in doctor-patient dialogue about HIV drug adherence depending on patients' race and ethnicity. Black patients experienced significant provider dominance, while Hispanic patients had more extensive dialogues about adherence.
Research found that drugs used to treat HIV penetrate poorly into lymphatic tissues, allowing persistent low-level virus replication. This replication may contribute to chronic immune activation and accelerated aging in patients.
A study in PLOS Genetics found that HIV drug resistance mutations can spread rapidly within a patient, leading to a homogeneous or heterogeneous viral population. The researchers estimate the effective population size of HIV to be around 150,000, which may help inform treatment strategies and predict resistance evolution.
Researchers from the University of Pennsylvania conducted a large-scale HIV intervention project in South Africa, involving nearly 1,200 individuals. The program showed significant improvements in condom use and reductions in unprotected sex among men, with participants reporting increased discussions about safe sex and condom use.
A study found that pro-inflammatory molecules were strongly associated with increased mortality in alcohol-abusing HIV patients. IL-6 was identified as the molecule most closely linked to mortality, regardless of antiretroviral therapy use. This research may inform strategies to improve mortality rates among this vulnerable population.
Researchers at Duke University have determined the structure of a key part of the HIV envelope protein, gp41 membrane proximal external region (MPER), which previously eluded detailed structural description. This discovery will help focus HIV vaccine development efforts.
A team led by The Wistar Institute will conduct a 4-year, randomized clinical trial to test an immunotherapy strategy that has shown promise in reducing the amount of persistent HIV-1 virus residing in cells. The trial aims to establish the effectiveness of this approach in advancing an HIV cure.
Researchers at UNC School of Medicine deploy a combination therapy targeting persistent HIV-infected cells that standard therapies cannot kill. The study uses mouse models and finds that an antibody combined with a bacterial toxin can penetrate infected cells and kill them, resulting in a six-fold drop in the number of infected cells.
The Population Council is developing a non-antiretroviral HIV microbicide to prevent HIV and other STIs, particularly for women in sub-Saharan Africa. The project aims to create safe, effective, and acceptable products with the potential to deliver an additional prevention option globally.
The proportion of opioid treatment programs offering on-site testing for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) decreased substantially between 2000 and 2011, despite guidelines recommending routine opt-out HIV testing. For-profit opioid treatment programs were more likely to experience this decline.
University of Minnesota researchers have discovered a series of compounds with anti-HIV activity that block HIV DNA synthesis or induce lethal mutagenesis. The compounds, known as ribonucleoside analogs, stop the replication and spread of HIV by preventing it from reproducing.
The Microbicide Trials Network, led by the University of Pittsburgh, has received a seven-year, $70 million grant to continue developing and testing HIV prevention products. The network aims to address unmet needs for new products targeting young women and men who have sex with men.
Research presented at EuroEcho-Imaging 2013 found that HIV patients with a positive blood viral load have a significantly higher incidence of structural heart disease. The study suggests that HIV itself might be an independent causal agent, and having a detectable blood viral load nearly doubles the prevalence of heart disease.
A new study found that antiretroviral therapy has saved 2.8 million years of life in South Africa since 2004, with projections of an additional 15.1 million years saved by 2030. Aggressive HIV testing and treatment strategies could further increase these benefits.
A novel, multipurpose pod-intravaginal ring (pod-IVR) delivers up to five different antiretroviral drugs and two hormonal contraceptives, showing promise in preventing HIV and unintended pregnancy. This innovative device could empower women in resource-poor areas to protect themselves from infections.
Researchers found a protein, Sprouty-2, that causes loss of function in immune cells combatting HIV, but disabling it restored their ability to fight the virus. Disabling both Sprouty-2 and PD-1 in exhausted T cells reversed exhaustion completely.
A new aggressive HIV strain, A3/02, has been identified in West Africa and is associated with a shorter period of five years from infection to AIDS development. The study also highlights the increasing global spread of recombinant HIV forms, which can be more vigorous and aggressive than traditional strains.
Supplementation with multivitamins plus selenium reduced HIV disease progression, immune decline, and illness risk in antiretroviral therapy-naive adults in Botswana. The supplement delayed time to HIV disease progression and improved markers of immune function.
A study analyzing 23,373 inmates entering a state prison system in North Carolina found that only 0.09% were HIV seropositive and not previously known to be infected. This suggests that incarceration may not be a high-risk environment for new cases of undiagnosed HIV infection.
A study published in the Journal of the American Medical Association found that only 1.45% of new inmates in North Carolina prisons tested positive for HIV, with most having previously been diagnosed. The findings suggest that screening incoming prisoners may not be an effective strategy for detecting new undiagnosed cases.
A University of Missouri researcher found that photovoice empowered women living with HIV to realize their strengths despite struggles. The project allowed them to reflect on their experiences and appreciate the present, giving them hope and motivation.
A recent study published in Clinical Infectious Diseases suggests that even those with low viral loads are at risk of treatment failure. Patients with persistent viral loads between 50-999 copies/mL have a significantly higher risk of virologic failure, which can lead to disease progression.
A collaborative team, led by Prof. Mark Williams, reveals how the APOBEC3G protein forms a roadblock to prevent HIV replication, offering new avenues for HIV therapy and drug development.
Research by Case Western Reserve University found that younger individuals with HIV are more likely to experience social isolation and stress due to stigma and limited support networks. In contrast, older adults with HIV were found to have developed social connections and coping mechanisms that helped mitigate these effects.
Research found strong partner communication about HIV and being in a committed relationship are key predictors of HIV testing among teens. High HIV knowledge was not associated with increased testing rates.
A new study investigated the needs of young people with HIV who want to become parents, revealing concerns over transmission and relationship impacts. The research found that these individuals face unique challenges in communicating their HIV status to partners and navigating parenting responsibilities.
A study by St. Michael's Hospital found that youth prefer rapid point-of-care HIV testing due to its speed and non-invasiveness. The test provides results within minutes, making it ideal for transient or homeless youth who may not return for follow-up appointments.
The Los Alamos National Laboratory team has developed a novel approach to estimating epidemic dynamics, capturing the full infection history and social network interactions. The model allows for realistic simulation of epidemics with known parameters of human interactions.
Scientists at Caltech created a lab-on-a-chip device using SlipChip technology that can accurately measure the concentration of HIV RNA molecules in a sample. The digital approach uses amplification chemistry to produce a fluorescent signal, allowing for precise quantification despite changes in environmental conditions.
The updated HIV care guidelines recommend focusing on preventive care, including screening for high cholesterol, diabetes, and osteoporosis. Primary care physicians should also be familiar with HIV care recommendations to provide comprehensive care to patients with HIV infection.
Researchers at KU Leuven developed a new protein fusion that combines HIV and MLV replication proteins to create a safer viral vector for gene therapy. This fusion protein reduces the risk of cancer-causing mutations when integrated into human cells, paving the way for more effective treatments for blood diseases.
A new intravaginal ring has been developed to deliver tenofovir and levonorgestrel, providing dual protection against HIV and unintended pregnancy. The ring shows promising results in preclinical trials, with local levels of tenofovir similar to those achieved with a gel.
The Infectious Diseases Society of America has launched a new open access journal, Open Forum Infectious Diseases, which will publish clinical, translational, and basic research findings in infectious diseases. The journal will be fully peer-reviewed and accessible online at no cost.
Researchers have identified a molecular invisibility cloak that enables HIV to hide in cells, but exposing it triggers an immune response. This discovery could lead to new treatments and improve existing therapies for HIV infection.
Key findings include the potential for affordable bridge therapy, a potential solution for those on ART developing aging-related diseases, and a possible clearing of the latent reservoir that could contribute to a cure. A vaccine is also being explored, with promising avenues including monoclonal broadly neutralizing antibodies.
A U.S.-based analysis by University of Pittsburgh researchers suggests that bisexual men may not be responsible for significant HIV transmission to their female partners. The study found that bisexually behaving men were only 40% as likely to be infected with HIV as homosexually behaving men, primarily due to lower rates of unprotected...